Press Releases Items Per Page 102550 Year None202020192018201720162015201420132012201120102007 02.22.18 Syndax Announces Presentations at the 2018 American Association for Cancer Research Annual Meeting 02.01.18 Syndax Announces Immuno-Oncology Clinical Trial Collaboration with AstraZeneca 01.10.18 Syndax Pharmaceuticals Announces Clinical Collaboration to Evaluate Entinostat in Combination with anti-PD-L1 Cancer Immunotherapy in Breast Cancer 11.11.17 Syndax Pharmaceuticals Announces Presentation of Data from Immuno-oncology Clinical Trials at the Society for Immunotherapy of Cancer 32nd Annual Scientific Meeting 11.07.17 Syndax Pharmaceuticals Reports Third Quarter 2017 Financial Results and Provides Clinical and Business Update 11.07.17 Syndax to Present at the SITC 32nd Annual Scientific Meeting 10.31.17 Syndax to Announce Third Quarter 2017 Financial Results and Host Conference Call and Webcast on November 7, 2017 10.17.17 Syndax Announces $25 Million Registered Direct Offering of Common Stock 10.17.17 Syndax Expands Pipeline with Exclusive Worldwide License to Allergan's Portfolio of Menin-MLL Inhibitors 10.05.17 Syndax Announces Dosing of First Patient in Pivotal Trial of Entinostat for the Treatment of Advanced or Recurrent Breast Cancer in Japan by Partner Kyowa Hakko Kirin 09.20.17 Syndax Pharmaceuticals Announces Updated Presentation Time at the Cantor Fitzgerald Global Healthcare Conference 08.30.17 Syndax Pharmaceuticals Announces Participation at Three Upcoming Investor Conferences Pagination First page « first Previous page ‹ previous … Page 3 Page 4 Page 5 Page 6 Current page 7 Page 8 Page 9 Page 10 Page 11 … Next page next › Last page last »
02.22.18 Syndax Announces Presentations at the 2018 American Association for Cancer Research Annual Meeting
01.10.18 Syndax Pharmaceuticals Announces Clinical Collaboration to Evaluate Entinostat in Combination with anti-PD-L1 Cancer Immunotherapy in Breast Cancer
11.11.17 Syndax Pharmaceuticals Announces Presentation of Data from Immuno-oncology Clinical Trials at the Society for Immunotherapy of Cancer 32nd Annual Scientific Meeting
11.07.17 Syndax Pharmaceuticals Reports Third Quarter 2017 Financial Results and Provides Clinical and Business Update
10.31.17 Syndax to Announce Third Quarter 2017 Financial Results and Host Conference Call and Webcast on November 7, 2017
10.17.17 Syndax Expands Pipeline with Exclusive Worldwide License to Allergan's Portfolio of Menin-MLL Inhibitors
10.05.17 Syndax Announces Dosing of First Patient in Pivotal Trial of Entinostat for the Treatment of Advanced or Recurrent Breast Cancer in Japan by Partner Kyowa Hakko Kirin
09.20.17 Syndax Pharmaceuticals Announces Updated Presentation Time at the Cantor Fitzgerald Global Healthcare Conference
